Bind Therapeutics deal with AstraZeneca similar to other deals, Reuters reports

theflyonthewall.com

AstraZeneca (ZN) is to pay privately held Bind Therapeutics as much as $200M to develop a cancer medicine using its nanotechnology drug delivery system, reports Reuters. Earlier this year Bind struck similar deals with Amgen (AMGN) and Pfizer (PFE).

View Comments (0)